Literature DB >> 26167455

Asymptomatic hyperuricemia following renal transplantation.

Gianni Bellomo1.   

Abstract

Evidence is accumulating indicating a role for uric acid in the genesis and progression of kidney disease, and a few studies are beginning to show a possible beneficial effect of urate-lowering therapy. Whether this holds true for renal allograft recipients is not clear. In this short review evidence from epidemiological as well as intervention studies is summarized and discussed, with some practical considerations presented at the end.

Entities:  

Keywords:  Allopurinol; Febuxostat; Renal transplant; Urate lowering therapy; Uric acid

Year:  2015        PMID: 26167455      PMCID: PMC4491922          DOI: 10.5527/wjn.v4.i3.324

Source DB:  PubMed          Journal:  World J Nephrol        ISSN: 2220-6124


  40 in total

1.  Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival.

Authors:  Kazuyuki Numakura; Shigeru Satoh; Norihiko Tsuchiya; Mitsuru Saito; Shinya Maita; Takashi Obara; Hiroshi Tsuruta; Takamitsu Inoue; Shintaro Narita; Yohei Horikawa; Hideaki Kagaya; Masatomo Miura; Tomonori Habuchi
Journal:  Transplantation       Date:  2012-07-27       Impact factor: 4.939

2.  Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients.

Authors:  T Tojimbara; I Nakajima; J Yashima; S Fuchinoue; S Teraoka
Journal:  Transplant Proc       Date:  2014       Impact factor: 1.066

3.  Hyperuricemia after renal transplantation.

Authors:  E Kalantar; N Khalili; M-S Hossieni; Z Rostami; B Einollahi
Journal:  Transplant Proc       Date:  2011-03       Impact factor: 1.066

Review 4.  Uric acid as a target of therapy in CKD.

Authors:  Diana I Jalal; Michel Chonchol; Wei Chen; Giovanni Targher
Journal:  Am J Kidney Dis       Date:  2012-10-09       Impact factor: 8.860

5.  Hyperuricemia in adult renal allograft recipients: prevalence and predictors.

Authors:  J Malheiro; M Almeida; I Fonseca; L S Martins; S Pedroso; L Dias; A C Henriques; A Cabrita
Journal:  Transplant Proc       Date:  2012-10       Impact factor: 1.066

6.  The independent association between serum uric acid and graft outcomes after kidney transplantation.

Authors:  Abdolreza Haririan; Joseph M Nogueira; Joseph M Noguiera; Kambiz Zandi-Nejad; Ravi Aiyer; Heather Hurley; Matthew Cooper; David K Klassen; Matthew R Weir
Journal:  Transplantation       Date:  2010-03-15       Impact factor: 4.939

Review 7.  Uric acid and chronic kidney disease: which is chasing which?

Authors:  Richard J Johnson; Takahiko Nakagawa; Diana Jalal; Laura Gabriela Sánchez-Lozada; Duk-Hee Kang; Eberhard Ritz
Journal:  Nephrol Dial Transplant       Date:  2013-03-29       Impact factor: 5.992

8.  Moderate-to-severe early-onset hyperuricaemia: a prognostic marker of long-term kidney transplant outcome.

Authors:  Sang Il Min; Ik Jin Yun; Jin Mo Kang; Yang Jin Park; Seung Kee Min; Curie Ahn; Sang Joon Kim; Jongwon Ha
Journal:  Nephrol Dial Transplant       Date:  2009-04-25       Impact factor: 5.992

9.  Is uric acid a predictive factor for graft dysfunction in renal transplant recipients?

Authors:  A Akgul; A Bilgic; A Ibis; F N Ozdemir; Z Arat; M Haberal
Journal:  Transplant Proc       Date:  2007-05       Impact factor: 1.066

Review 10.  Effects of hyperuricemia on renal function of renal transplant recipients: a systematic review and meta-analysis of cohort studies.

Authors:  Yan Huang; Yu-Lin Li; He Huang; Ling Wang; Wen-Ming Yuan; Jing Li
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

View more
  2 in total

Review 1.  Uric Acid and Arterial Stiffness.

Authors:  Adriana Albu; Ioana Para; Mihai Porojan
Journal:  Ther Clin Risk Manag       Date:  2020-01-28       Impact factor: 2.423

Review 2.  Prevalence of Musculoskeletal Manifestations in Adult Kidney Transplant's Recipients: A Systematic Review.

Authors:  Adla B Hassan; Kanz W Ghalib; Haitham A Jahrami; Amgad E El-Agroudy
Journal:  Medicina (Kaunas)       Date:  2021-05-23       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.